id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-265230-ozyx8u64	Takahari, Daisuke	Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research	2020-10-21		.txt	text/plain	5741	276	42	In order to reduce the use of medical resources to avoid the risk of COVID-19 infections in both cancer patients and health care providers, oncologists now have to draw the line for cancer treatments by maintaining their efficacy while avoiding severe adverse events. By contrast, for treating patients with high risk and/or during the pandemic, we must choose between reducing the intensity of chemotherapy (e.g., omission of the 5-FU bolus for CRC, replacement of infusional 5-FU by capecitabine or S-1 for ESCC, gastric cancer (GC), and CRC), delaying treatment, skipping cycles, or stopping (i.e., treatment maintenance phase and salvage chemotherapy with relatively few benefits). As first-line chemotherapy, for patients with high tumor burden or tumor-related signs/symptoms or low risk of COVID-19 infection, combination of fluoropyrimidine and oxaliplatin (if HER2 is positive, plus trastuzumab) is recommended as a standard regimen [38] .	./cache/cord-265230-ozyx8u64.txt	./txt/cord-265230-ozyx8u64.txt